(Q35539676)

8 August 2017

1 reference

title

Clinical trial design and outcomes in patients with severe sepsis (English)

1 reference

8 August 2017

Clinical Trial Design and Outcomes in Patients with Severe Sepsis (English)

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

12 March 2024

0 references

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

12 March 2024

1

Steven M Opal

1 reference

8 August 2017

Steven M. Opal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14501941

12 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14501941

12 March 2024

publication date

1 October 2003

1 reference

8 August 2017

1 reference

8 August 2017

volume

20

1 reference

8 August 2017

issue

4

1 reference

8 August 2017

page(s)

295-302

1 reference

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

8 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment

12 March 2024

2

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

The sirens' songs of confirmatory sepsis trials: selection bias and sampling error.

12 March 2024

3

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Has the mortality of septic shock changed with time

12 March 2024

4

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Clinical trials for severe sepsis. Past failures, and future hopes

12 March 2024

5

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Clinical gram-positive sepsis: does it fundamentally differ from gram-negative bacterial sepsis?

12 March 2024

6

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Therapy of sepsis: why have we made such little progress?

12 March 2024

7

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Cytokines and anticytokines in the pathogenesis of sepsis

12 March 2024

8

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

The uncertain value of the definition for SIRS. Systemic inflammatory response syndrome

12 March 2024

9

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies

12 March 2024

10

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Time course of hemostatic abnormalities in sepsis and its relation to outcome.

12 March 2024

11

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Relation between dicrotic notch and mean pulmonary artery pressure studied by using a Swan-Ganz catheter in critically ill patients

12 March 2024

12

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Low levels of protein C are associated with poor outcome in severe sepsis

12 March 2024

13

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock

12 March 2024

14

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Efficacy and safety of recombinant human activated protein C for severe sepsis

12 March 2024

15

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine

12 March 2024

16

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference

12 March 2024

17

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction

12 March 2024

18

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis

12 March 2024

19

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

The haematological manifestations of sepsis

12 March 2024

21

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial

12 March 2024

22

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation

12 March 2024

25

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study.

12 March 2024

26

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Intensive insulin therapy in critically ill patients

12 March 2024

27

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells

12 March 2024

29

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control

12 March 2024

30

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Early goal-directed therapy in the treatment of severe sepsis and septic shock

12 March 2024

31

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Accidental removal of endotracheal and nasogastric tubes and intravascular catheters.

12 March 2024

32

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock

12 March 2024

33

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Cortisol replacement for severe sepsis and septic shock: what should I do?

12 March 2024

34

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Corticosteroids for patients with septic shock

12 March 2024

35

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Corticosteroids for patients with septic shock

12 March 2024

36

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant

12 March 2024

37

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Epidemic meningococcemia and purpura fulminans with induced protein C deficiency

12 March 2024

38

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Changes of the hemostatic network in critically ill patients--is there a difference between sepsis, trauma, and neurosurgery patients?

12 March 2024

39

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Protein C levels as a prognostic indicator of outcome in sepsis and related diseases

12 March 2024

40

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Dysfunction of Endothelial Protein C Activation in Severe Meningococcal Sepsis

12 March 2024

41

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon

12 March 2024

42

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Endothelial cell protein C receptor plays an important role in protein C activation in vivo

12 March 2024

43

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis

12 March 2024

44

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Treatment of purpura fulminans in meningococcemia with protein C concentrate

12 March 2024

45

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans

12 March 2024

46

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis

12 March 2024

48

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis

12 March 2024

49

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Risks and benefits of activated protein C treatment for severe sepsis

12 March 2024

50

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Assessing the use of activated protein C in the treatment of severe sepsis

12 March 2024

51

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

APACHE II: a severity of disease classification system

12 March 2024

52

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Activated Protein C for Severe Sepsis

12 March 2024

53

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Baseline cortisol levels, cortisol response to corticotropin, and prognosis in late septic shock

12 March 2024

55

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

Early interleukin-10 treatment improves survival and enhances immune function only in males after hemorrhage and subsequent sepsis

12 March 2024

56

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

A prospective study of inflammation markers in patients at risk of indirect acute lung injury.

12 March 2024

58

1 reference

https://api.crossref.org/works/10.1097/01.SHK.0000084343.58020.57

12 March 2024

Identifiers

1 reference

8 August 2017

1 reference